A Phase 2, Multicenter, Multi-cohort, Open-label Study of Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide Based Therapy in the First or Second Line Setting
Latest Information Update: 31 Jul 2023
At a glance
- Drugs Pomalidomide (Primary) ; Daratumumab; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 15 Jun 2023 Results of final overall survival in MM-014 cohort B at a median follow-up of 41.9 months, presented at the 28th Congress of the European Haematology Association.
- 01 Jul 2022 Results published in the International Journal of Hematology
- 01 Jun 2022 Updated efficacy, safety and health-related quality of life results were published in the Leukemia and Lymphoma.